Generation IV Therapeutic Vaccine for Chronic Hepatitis B
NL Biotechnologies has developed the generation IV therapeutic vaccine for chronic Hepatitis B. The vaccine is based on yeast-rDNA technology and uniquely combines all four structural proteins of HBV. Unlike previous generations of Hepatitis B vaccines, NL Biotechnologies has noted that, the combination of all four proteins induces an array of antiviral neutralizing antibodies and stimulates virus-specific cellular immunity.
Even in healthy individuals, previous generations of Hepatitis B vaccines have only targeted in a prophylactic way to stop the dissemination of the hepatitis B virus. Individuals with chronic Hepatitis B (CHB) have rarely shown clearance and sustained response to antiviral treatment. NL Biotechnologies’ generation IV therapeutic vaccine for chronic Hepatitis B is the first safe and effective therapeutic solution for CHB patients. Noted advantages over conventional therapy include long term (probably lifelong), low cost specificity against hepatitis B virus infection and fewer injections.
The technology for NL Biotechnologies’ generation IV therapeutic vaccine for chronic Hepatitis B is based on recombinant DNA, and yeast genetic methods that allow constructing plasmids encoding hepatitis B viral structural proteins and their expression in Hansenula polymorpha cells. Once the yeast has transformed and plasmid has been successfully integrated, the culture of yeast cells is forced to simultaneously produce the target proteins combining cells growth and expression. Cells collecting the targeted proteins are then extracted. Physical-chemical methods then isolate the target proteins in the form of virus like particles (VLP). The final product consists of 3 separate antigens expressed: HBsAg, HBs-PreS1-PreS2 chimera and HBcAg with the purity rate not less than 95%.
NL Biotechnologies is able to provide samples of the vaccine components, as well as, samples of the ready-to-use vaccine. Samples may be used in preclinical trials of the vaccine. NL Biotechnologies’ specialists can offer demonstrations. All technology is ready for transfer to a designated facility for scale up.
Intellectual property rights for this vaccine are protected by patent pending in Russia.
For more information or to discuss generation IV therapeutic vaccine for chronic Hepatitis B please contact us directly.
